美托洛尔对扩张型心肌病心力衰竭患者的影响

Efficacy of metoprolol in dilated cardiomyopathy patients with chronic heart failure

目的观察美托洛尔治疗扩张型心肌病心力衰竭患者的疗效。方法将65例扩张型心肌病并出现心力衰竭患者随机分为A、B两组。两组基本用药类同,均应用血管紧张素转化酶抑制剂、利尿剂和洋地黄制剂。A组在此基础上加用美托洛尔。定期门诊随访,观察治疗前后临床心功能NYHA分级,超声心动图检查等项目。结果A组与B组比较,治疗后美托洛尔组左室舒张末期内径和左室收缩末期内径分别为(54.6±6.7)mm和(38.7±3.9)mm,显著低于常规治疗组(56.5±6.8)mm和(39.9±4.6)mm;左室射血分数为(38.6±3.1)%,显著高于常规治疗组(34.1±2.7)%,P<0.01。心功能改善(P<0.05),病情恶化减少(P<0.05)。结论扩张型心肌病心力衰竭患者长期服用美托洛尔可使心功能改善。

Objective To evaluate the effect of metorprolol on the cardiac function in patients with chronic heart failure （CHF）. Methods 65 patients with CHF Were divided randomly into two groups, one was regular treatment group treated with ACE inhibitor, digoxin and diuretic, another was metorprolol treatment group treated group treated with metoprolol on the basis of above regular treatment. All the patients were followed up for six months and measured the changes of cardiac function. Results After metoprolol treatment, LVEDD and LVESD （54.6 ± 6.7） mm and （38.7 ± 3.9） mm, were shorter than that in regular treatment group [（56.5±6.8）mm and （39.9±4.6）mm],and LVEF[（38.6±3.1）%] was higher than that [（34.1 ±2.7）%] in regular treatment group（ P 〈 0.01 ）. Conclusion Metoprolol can improve hemodynamics in dilated eardiomyopathy patients with chronic heart failure.